Compare BridgeBio Pharma Inc (BBIO) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs J M Smucker Co — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while J M Smucker Co trades at $117.46 (market cap $12.84B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and J M Smucker Co pays a 3.73% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SJM | |
|---|---|---|
Market Cap | $16.61B | $12.84B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $126.35 |
52-Week Low | $47.29 | $89.53 |
Enterprise Value | $18.16B | $19.87B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
SJM trades at $120.16, up 1.14% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 results are pending. The company maintains a solid dividend track record, raising payouts for 25 consecutive years. Revenue growth is stable, but negative net income and ROE highlight profitability challenges amid high debt levels.
Outlook is cautiously optimistic with a consensus price target of $125.11 offering 4% upside. Key risks include persistent negative margins and elevated leverage, while opportunities lie in cost controls and brand strength. Investors should weigh dividend reliability against earnings volatility in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
